Contrary to expectation: Preserved renal function after using PD-1 Inhibitor Cemiplimab-rwlc in a kidney transplant recipient

• Главные авторы: Muhannad Leghrouz (Автор), Svetomir N Markovic (Автор), Aleksandra Kukla (Автор)
• Формат: ‌
• Опубликовано: Archives of Organ Transplantation - Peertechz Publications, 2022-09-08.
• Предметы: Case Report
• Online-ссылка: Connect to this object online.

<p>The use of immune checkpoint inhibitors in transplant recipients with malignancy is associated with the risk of graft failure due to acute rejection. There is limited literature regarding the use of Cemiplimab-rwlc (Libtayo) in kidney transplant patients. Here we present a case of using Cem...